RT Journal Article SR Electronic T1 Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome JF Cancer Genomics - Proteomics JO Cancer Genomics Proteomics FD International Institute of Anticancer Research SP 225 OP 236 DO 10.21873/cgp.20183 VO 17 IS 3 A1 SERENA LACERENZA A1 FEDERICA CIREGIA A1 LAURA GIUSTI A1 ALESSANDRA BONOTTI A1 VIVIANA GRECO A1 GINO GIANNACCINI A1 VANESSA D'ANTONGIOVANNI A1 POUPAK FALLAHI A1 LUISA PIERONI A1 ALFONSO CRISTAUDO A1 ANTONIO LUCACCHINI A1 MARIA ROSA MAZZONI A1 RUDY FODDIS YR 2020 UL http://cgp.iiarjournals.org/content/17/3/225.abstract AB Background: Malignant pleural mesothelioma (MPM) a rare neoplasm linked to asbestos exposure is characterized by a poor prognosis. Soluble mesothelin is currently considered the most specific diagnostic biomarker. The aim of the study was to identify novel biomarkers by proteomic analysis of two MPM cell lines secretome. Materials and Methods: The protein patterns of MPM cells secretome were examined and compared to a non-malignant mesothelial cell line using two-dimensional gel electrophoresis coupled to mass spectrometry. Serum levels of candidate biomarkers were determined in MPM patients and control subjects. Results: Two up-regulated proteins involved in cancer biology, prosaposin and quiescin Q6 sulfhydryl oxidase 1, were considered candidate biomarkers. Serum levels of both proteins were significantly higher in MPM patients than control subjects. Combining the data of each receiver-operating characteristic analysis predicted a good diagnostic accuracy. Conclusion: A panel of the putative biomarkers represents a promising tool for MPM diagnosis.